Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32691742 | 0.83 | NOTUM (0.36) | NOTUM | |
| SCHEMBL6551232 | 0.82 | NOTUM (0.35) | NOTUM | |
| SCHEMBL3282414 | 0.78 | NOTUM (0.41) | NOTUM | |
| SCHEMBL6551234 | 0.73 | NOTUM (0.37) | NOTUM | |
| SCHEMBL25288671 | 0.71 | AKR1C3 (0.42) | NOTUM | |
| SCHEMBL9300394 | 0.71 | MEN1 (0.39) | NOTUM | |
| SCHEMBL6551187 | 0.69 | — | — | |
| SCHEMBL14065426 | 0.68 | HTR6 (0.36) | — | |
| SCHEMBL8959947 | 0.68 | NOTUM (0.37) | NOTUM | |
| SCHEMBL3437628 | 0.68 | CFD (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6660494-B2 | Detecting phosphatidylcholine-specific phospholipase-C enzyme via incorporation of 3-indoxyl choline phosphate into substrate | BIOSYNTH AG (CH) | 2003-12-09 | — | — | US | disclosed |
| EP-1219628-B1 | Novel substrates for detection of microbial metabolites | BIOSYNTH AG (CH) | 2003-04-02 | — | — | EP | disclosed |
| US-20020151725-A1 | Detection of microbial metabolites | BIOYNTH AG (CH) | 2002-10-17 | — | — | US | disclosed |
| EP-1219628-A1 | Novel substrates for detection of microbial metabolites | Biosynth AG (CH) | 2002-07-03 | — | — | EP | disclosed |
| US-6068988-A | DETECTING A PHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE C IN A SAMPLE BY CONTACTING WITH A CHROMOGENIC SUBSTRATE AND MONITORING FOR COLOR FORMATION | BIOSYNTH AG (CH) | 2000-05-30 | — | — | US | disclosed |
| US-6051391-A | SUBSTRATE FOR ANALYSIS OF PHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE C WHICH INCLUDES 3-INDOXYL-MYO-INOSITOL-1-PHOSPHATE DERIVATIVE OR SALT; COLORIMETRIC ANALYSIS AND PLATING MEDIA | BIOSYNTH AG (CH) | 2000-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151725-A1 | Detection of microbial metabolites | LCT, CEL, PLCB1 | NOTUM 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.